BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update

Company Overview - BrainStorm Cell Therapeutics Inc. is a leading developer of autologous adult stem cell therapies for neurodegenerative diseases, utilizing its proprietary NurOwn® platform to produce neurotrophic factor-secreting cells [5] - The company focuses on therapies for conditions such as amyotrophic lateral sclerosis (ALS) and progressive multiple sclerosis (MS) [6] Upcoming Conference Call - A conference call is scheduled for August 14, 2025, at 8:30 AM Eastern Time to update shareholders on the financial results for the second quarter of 2025 [1] - Key executives participating in the call include President and CEO Chaim Lebovits, COO Hartoun Hartounian, CMO Bob Dagher, and Interim CFO Alla Patlis [2] Clinical Development - NurOwn® has received Orphan Drug designation from both the U.S. FDA and the European Medicines Agency (EMA) for ALS treatment [6] - A Phase 3 trial for ALS has been completed, and a second Phase 3b trial is set to launch under a Special Protocol Assessment (SPA) agreement with the FDA [6] - The clinical program has provided insights into ALS disease biology, including pharmacogenomic responses and biomarker data [6] Intellectual Property - BrainStorm has received a Notice of Allowance from the U.S. Patent and Trademark Office for a foundational patent covering its exosome technology, enhancing its intellectual property portfolio in regenerative medicine [6]